Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Panel Conditionally OKs Change to Allow Use of Abortion Pill at Clinics Without Beds
Japan’s health ministry panel on August 26 gave an OK to a proposal to expand the current system for the use of Mefeego Pack (mifepristone/misoprostol), the first abortion pill approved in the country last year. The Pharmaceutical Affairs Council’s (PAC)…
To read the full story
Related Article
- Japan Partially Eases Rule for Use of Abortion Pill Mefeego
December 2, 2024
- MHLW Panel Puts a Hold on Proposed Use of Abortion Pill at Clinics Without Beds
September 26, 2024
- LDP Members Fret over Easier Access to Abortion Pill Mefeego
July 29, 2024
- 68.3% of Public Comments Supported Mefeego Approval: MHLW
May 16, 2023
- Japan Approves Mefeego as First Abortion Pill
May 1, 2023
- Abortion Pill Mefeego’s Japan Panel Review Rescheduled for April 21
April 18, 2023
- Public Comments 2 to 1 in Favor of Approving Abortion Pill: MHLW
March 27, 2023
REGULATORY
- LDP Project Team Flags Drug Pricing as Key to Investment
March 19, 2026
- Japan Sets Up Radiopharma Discovery Hub in Fukushima, Targets Rare Cancers
March 18, 2026
- MHLW Seeks Industry Survey on Petroleum-Linked Products amid Iran Crisis
March 18, 2026
- MHLW Orders Label Revisions for Antiepileptics and Other Drugs
March 18, 2026
- MHLW Panel OKs Draft Criteria for “Specified Medical Technologies”
March 17, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…